Clinical Trial

Study on Ginkgo Biolba Extract Fifty and Mild Cognitive Impairment Associated With CSVD

Study acronym: GRACE
Not Yet Recruiting Phase 4
View on ClinicalTrials.gov →
Record status
This record was last updated August 28, 2024 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
This study aimed to explore the efficacy and safety of Ginkgo Biolba Extract fifty in treating mild cognitive impairment associated with cerebral small vessel disease (CSVD). Subjects included based on eligibility criteria were randomized into treatment and control groups. Patients will receive the drug or placebo for 12 months. Patients were followed at baseline and at 3 months, 6 months, and 12 months after randomization. The primary outcome was the difference from baseline in the Montreal Cognitive Assessmen (MoCA) score at 12 months after randomization.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-07-08.
Trial Details
NCT Number NCT06495476
Lead Sponsor Beijing Tiantan Hospital
Conditions Mild Cognitive Impairment
Enrollment 144 participants
Start Date 2024-09-01
Primary Completion 2025-12-31 (estimated)
Study Completion 2026-06-30 (estimated)
Updated on ClinicalTrials.gov 2024-08-28